Related Experiment Videos
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
Zachary R Hunter1, Andrew R Branagan, Robert Manning
1Bing Program for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, LG102, 44 Binney Street, Boston, MA 02215, USA.
Clinical Lymphoma
|March 30, 2005
Summary
CD5, CD10, and CD23 cell surface antigens are frequently expressed in Waldenstrom's macroglobulinemia (WM). Their presence does not exclude a WM diagnosis and CD23 expression may indicate a distinct patient subset.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Cell surface antigens CD5, CD10, and CD23 are crucial for diagnosing B-cell disorders.
- Their expression and clinical significance in Waldenstrom's macroglobulinemia (WM) are not fully understood.
- WM is a rare lymphoplasmacytic B-cell lymphoma.
Purpose of the Study:
- To determine the expression of CD5, CD10, and CD23 in Waldenstrom's macroglobulinemia (WM).
- To correlate antigen expression with clinical and laboratory data.
- To investigate the potential for familial predisposition in WM.
Main Methods:
- Flow cytometric analysis of bone marrow lymphoplasmacytic cells (CD19+, kappa/lambda light chain restricted) from 171 patients meeting WM criteria.
- Correlation of antigen expression with clinical parameters, serum immunoglobulin levels, and familial history.
Main Results:
- CD5, CD10, and CD23 were expressed in 9%, 7%, and 35% of WM patients, respectively.
- Coexpression of CD23 with CD5 or CD10 was common.
- CD23 expression was associated with higher serum IgM levels, suggesting a distinct clinical subset.
Conclusions:
- CD5, CD10, and CD23 are commonly expressed in WM and should not preclude diagnosis.
- Expression of these antigens does not correlate with age, organomegaly, bone marrow involvement, or familial history.
- CD23 expression may identify a clinically distinct subgroup of WM patients.